
Company Location

810 East Hammond Lane
Phoenix, AZ 85034

Contact Numbers

Tel: (602)254-6620

Contact

John McGill

Title: Director of Cytogenetics

John.mcgill@impath.com

Overview

Around the world, Genzyme's more than 5,000 employees are united by our common and constant commitment to patients. As individuals and as a company, we turn our talents and efforts to making a major positive impact on the lives of patients with difficult diseases. This commitment gives us a sense of urgency that propels us to develop and deliver therapies and diagnostics, to insist on excellence, to act with integrity and openness. It also underlies our entrepreneurial culture and global organization. It encourages us to come together in diverse and productive teams. Above all, it inspires each one of us with the knowledge that every day, in any circumstance, an individual can make an important, beneficial difference.

Research

Genzyme's product development program has a singular goal: developing innovative products and services for major unmet medical needs. With twenty years of experience working towards meeting this goal, Genzyme has developed centers of excellence in certain medical areas where it has either developed breakthrough products or made a major contribution to the scientific understanding of disease pathways.

- Lysosomal Storage Disorders
- Immune Mediated Diseases
- Adhesion Prevention
- Renal Disease
- Orthopaedics
- Cancer
- Cardiovascular
- Chronic Debilitating Diseases

Press Release Regarding Impath

The addition of IMPATH's cancer diagnostic business - together with Genzyme's acquisition of ILEX Oncology - will significantly expand the company's presence across the entire continuum of oncology patient care, from diagnosis to treatment. Through the IMPATH acquisition, Genzyme will obtain a leading array of oncology diagnostics in solid-tumor and blood-based cancers, testing laboratories in New York City, Phoenix and Los Angeles, and a strong team of board-certified anatomic and clinical pathologists with extensive experience in oncology testing. Genzyme plans to maintain operations at IMPATH's facilities and hire substantially all of IMPATH Physician Services' employees.

"Genzyme Genetics is very pleased to have the opportunity to combine with IMPATH Physician Services, which has earned and maintained strong customer loyalty by delivering high quality testing services with a focus on patient care," said Mara Aspinall, president, Genzyme Genetics. "We believe the market for oncology testing will continue to grow, fueled by the development of new sophisticated tests and treatments for cancer. While we increase our involvement in cancer testing, we will maintain and strengthen our core commitment to prenatal testing."

Carter H. Eckert, chairman and chief executive officer of IMPATH Inc., said, "We are delighted to announce this transaction especially in light of the quality reputation that Genzyme and its talented management team have earned over the years."